Top

Published in:

01-02-2012 | Original Article

Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

Authors: Hiroki Ochiai, Takashi Ohishi, Koji Osumi, Jo Tokuyama, Hidejirou Urakami, Shikou Seki, Atsushi Shimada, Akira Matsui, Yoh Isobe, Yuya Murata, Takashi Endo, Yoshiyuki Ishii, Hirotoshi Hasegawa, Sumio Matsumoto, Yuko Kitagawa

Published in: Surgery Today | Issue 2/2012

Abstract

Purpose

We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007.

Methods

S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9).

Results

S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%).

Conclusion

The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.

Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49–53.PubMedCrossRef

Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature (London). 1989;342(6250):705–8.CrossRef

Kawakami M, Yamaguchi T, Takahashi K, Matsumoto H, Yasutome M, Horiguchi S, et al. Assessment of SMAD4, p53, and Ki-67 alterations as a predictor of liver metastasis in human colorectal cancer. Surg Today. 2010;40(3):245–50.PubMedCrossRef

Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol. 1995;147(3):790–8.PubMed

Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990;335(8691):675–9.PubMedCrossRef

von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VM, Bennett WP, Liang L, et al. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res. 1996;56(21):4917–21.

Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266(5186):807–10.PubMedCrossRef

Hammel P, Leroy-Viard K, Chaumette MT, Villaudy J, Falzone MC, Rouillard D, et al. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer. 1999;81(5):712–8.PubMedCrossRef

Ralhan R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer. 2000;85(6):791–5.PubMedCrossRef

10.

Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer. 1995;72(3):637–41.PubMedCrossRef

11.

Takeda A, Nakajima K, Shimada H, Imaseki H, Takayama W, Hayashi H, et al. Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. J Surg Oncol. 1999;71(2):112–6.PubMedCrossRef

12.

Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M, et al. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci. 2000;45(1):122–8.PubMedCrossRef

13.

Broll R, Duchrow M, Oevermann E, Wellm C, Schwandner O, Schimmelpenning H, et al. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int J Colorectal Dis. 2001;16(1):22–7.PubMedCrossRef

14.

Takeda A, Shimada H, Nakajima K, Imaseki H, Suzuki T, Asano T, et al. Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Eur J Surg. 2001;167(1):50–3.PubMedCrossRef

15.

Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004;19(2):114–20.PubMedCrossRef

16.

Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33(2):272–7.PubMedCrossRef

17.

Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Cancer (Philadelphia). 2000;89(8):1677–83.CrossRef

18.

Takeda A, Shimada H, Nakajima K, Yoshimura S, Suzuki T, Asano T, et al. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol. 2001;6(1):45–9.PubMedCrossRef

19.

Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer (Philadelphia). 2003;97(3):682–9.CrossRef

20.

Tang R, Yeh CY, Wang JY, Changchien CR, Chen JS, Hsieh LL. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol. 2009;16(9):2516–23.PubMedCrossRef

21.

Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer. 2001;94(6):859–63.PubMedCrossRef

22.

Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer (Philadelphia). 1999;85(2):302–8.CrossRef

Title: Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients
Authors: Hiroki Ochiai
Takashi Ohishi
Koji Osumi
Jo Tokuyama
Hidejirou Urakami
Shikou Seki
Atsushi Shimada
Akira Matsui
Yoh Isobe
Yuya Murata
Takashi Endo
Yoshiyuki Ishii
Hirotoshi Hasegawa
Sumio Matsumoto
Yuko Kitagawa
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Surgery Today / Issue 2/2012
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-011-0044-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2012

Expanding the applications of microvascular surgical techniques to digestive surgeries: a technical review

Clinical application of an extracellular phosphate-buffered solution (EP-TU) for lung preservation: preliminary results of a Japanese series

Successful surgical treatment of advanced follicular thyroid carcinoma with tumor thrombus infiltrating the superior vena cava: report of a case

Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma

Digital evaluation of the muscle functions of the lower extremities among inguinal hernia patients treated using three different surgical techniques: a prospective randomized study

Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer